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Knowledge and attitude regarding
pharmacogenetics among formerly
pregnant women in the Netherlands and
their interest in pharmacogenetic research
Aizati N. A. Daud1,2*, Eefke L. Bergsma1, Jorieke E. H. Bergman3, Hermien E. K. De Walle3,
Wilhelmina S. Kerstjens-Frederikse3, Bert J. Bijker1, Eelko Hak1 and Bob Wilffert1,4
Abstract
Background: Pharmacogenetics is an emerging field currently being implemented to improve safety when prescribing
drugs. While many women who take drugs during pregnancy would likely benefit from such personalized drug therapy,
data is lacking on the awareness towards pharmacogenetics among women. We aim to determine the level of
knowledge and acceptance of formerly pregnant women in the Netherlands regarding pharmacogenetics and
its implementation, and their interest in pharmacogenetic research.
Methods: A population-based survey using postal questionnaires was conducted among formerly pregnant women
in the Northern parts of the Netherlands. A total of 986 women were invited to participate.
Results: Of the 219 women who returned completed questionnaires (22.2% response rate), only 22.8% had heard of
pharmacogenetics, although the majority understood the concept (64.8%). Women who had experience with drug
side-effects were more likely to know about pharmacogenetics [OR = 2.06, 95% CI 1.16, 3.65]. Of the respondents, 53.9%
were positive towards implementing pharmacogenetics in their future drug therapy, while 46.6% would be willing to
participate in pharmacogenetic research. Among those who were either not willing or undecided in this regard, their
concerns were about the consequences of the pharmacogenetic test, including the privacy and anonymity of their
genetic information.
Conclusion: The knowledge and attitude regarding the concept of pharmacogenetics among our population
of interest is good. Also, their interest in pharmacogenetic research provides opportunities for future research
related to drug use during pregnancy and fetal outcome.
Keywords: Medications, Personalized medicine, Pharmacogenetics in pregnancy, Pharmacogenetic test, Pregnancy
Background
Up to eight in ten pregnant women in developed countries
take prescription drugs—excluding prenatal supplements
and vitamins—at some time during their pregnancy [1–3].
Pregnancy can be a crucial period for these women, as
their drug efficacy and the risk of side-effects may change.
Various factors influence the pharmacokinetics of drugs
during pregnancy, including both physiological changes
and genetic factors [4–6]. Hence, in order to personalize
drug therapy for pregnant women it is imperative that this
process incorporates pharmacogenetics, i.e. knowledge of
the genetic factors involved in drug pharmacokinetics and
drug prescribing. Such personalization is especially im-
portant when managing pharmacotherapy in pregnant
women, since pre-registration trials have not yet studied
the risks of drugs in this high-risk group.
Although the implementation of pharmacogenetics in
drug prescribing is already underway, it is important to
* Correspondence: n.a.a.daud@rug.nl
1Department of Pharmacy, University of Groningen, Groningen Research
Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology &
-Economics, 9713AV Groningen, The Netherlands
2School of Pharmaceutical Sciences, Universiti Sains Malaysia, Discipline of
Clinical Pharmacy, 11800 Penang, Malaysia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Daud et al. BMC Pregnancy and Childbirth  (2017) 17:120 
DOI 10.1186/s12884-017-1290-z
ensure that the public is aware and understands this
new concept. In particular, they first need to allow doc-
tors to do pharmacogenetic testing before being pre-
scribed certain drugs that are subjected to dose changes
due to patient variability. According to one survey in
Denmark, the level of background knowledge on
pharmacogenetics among the general public is low
(14.1%) [7], although the majority of participants in
other studies conducted in Australia and the USA had a
positive attitude towards the concept [8–10]. However,
the knowledge and attitude regarding pharmacogenetics
specifically among pregnant women who also need to
take their unborn child into account in drug therapy,
has not yet been reported.
We therefore aimed to determine the level of knowledge
of pharmacogenetics among formerly pregnant women in
the Netherlands and identify the potential determinants
affecting their knowledge and attitude towards this con-
cept. Since pharmacogenetics is a relatively new field with
regard to drug therapy during pregnancy, it cannot be im-
plemented in a clinical setting until a suitable framework
is in place. Such a framework requires the results of obser-
vational pharmacogenetic studies, i.e. gene-environment
interaction studies, an increasing number of which are be-
ing conducted [11–14]. Therefore, we also explored the
interest of formerly pregnant women to participate in fu-
ture studies on pharmacogenetics.
Methods
Study design and settings
A population-based questionnaire was conducted be-
tween November 2015 and January 2016 to assess the
knowledge and attitude of formerly pregnant women re-
garding pharmacogenetics. The study population in-
cluded women who had been pregnant and had a history
of medication use at some time in their lives. These
women were identified from the University of Groningen
IADB.nl pharmacy prescription database. IADB.nl con-
tains the pharmacy data of approximately 600,000 people
in several Dutch provinces, provided by 60 community
pharmacies. The prescription rates of the IADB.nl popu-
lation are representative of the population in the
Netherlands [15]. Our study population was retrieved
from a pregnancy subset of IADB.nl, based on the link-
age between a child and a woman who was 15–50 years
older than the child and who shared the same home ad-
dress [16, 17]. Details of this linkage and of its validation
have been reported previously [18].
Participants
In November 2015, we selected participants who had
given birth between 1 January 2011 and 31 December
2014. This resulted in 3689 eligible women who were
registered over 37 pharmacies. Power analysis revealed
that reporting of associations between the dependent
variables (‘knowledge’, ‘attitude’ and ‘interest’) and deter-
minants as independent variables would require a total
of 135 respondents. This calculation was based on an
odds ratio of 2, an effect size of 0.3, 80% power and 5%
significance. As we estimated the response rate at 15%,
we selected approximately 1000 women whom we sent
the invitation letters.
We first selected community pharmacies that registered
the highest number of eligible women. These pharmacies
were invited to participate in the study by e-mail and/or
telephone. For each participating pharmacy, we used the
list of eligible women from the pregnancy subset of
IADB.nl to select participants at random. We continued
to invite the pharmacies until we reached 1000 eligible
women. For these women, we obtained their latest address
from the pharmacy and sent them a package containing
an invitation letter, a questionnaire coded with a unique
identification number, and a pre-paid return envelope.
Questionnaire
The questionnaires were in Dutch and divided into five
sections: a) personal information; b) experiences with dis-
eases and drug use; c) knowledge on pharmacogenetics; d)
attitude towards pharmacogenetics; and e) interest to par-
ticipate in pharmacogenetic research (Additional File 1).
The internal validity of the questionnaire was assessed by
a methodological advisor and members of the research
group, and some questions were subsequently revised to
be more precise and concise. The first draft of the ques-
tionnaire was tested on a pilot group of 25 women who
had a mean age of 26 years. They were sent either a paper
version or an electronic version of the questionnaire, to-
gether with accompanying questions aimed at assessing
their understanding of the content and its clarity; the
questionnaire was then revised accordingly.
The questions were mostly closed ended, with the op-
tions of ‘Yes/No/I don’t know’. The respondents were
allowed to leave blank answers. Since the concept of
pharmacogenetics is new to many, we provided a de-
scription of this term in the invitation letter and in sec-
tion c), after a series of questions to measure their
background knowledge. The description was as follows:
‘Pharmacogenetics looks at the influence of your genetic
traits on the effect of medication. It is possible that
different people break down medication differently due
to variations in their genetic traits’. Although pharma-
cogenetics is one of the subject areas within personalized
medicine, we do not introduce the broader terms (‘per-
sonalized medicine’, ‘precision medicine’, ‘individualized
medicine’) in the questionnaire. It is because we focused
on the relation between genetics and medication effects,
and not the genetic factors related to medical diagnosis,
therapy options, disease risk determination, etc.
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Statistical analysis
For statistical analysis, we grouped the level of education
reported by respondents into three levels: low (primary
school, lower general secondary education, and lower
vocational education), middle (higher general secondary
education and intermediate vocational education), and
high (higher vocational education and university). The
experiences with medication use and the responses to
questions on attitude and willingness were reported as
frequency and percentages. We used multivariable logis-
tic regression with complete case analysis to analyze as-
sociations between potential determinants (i.e. age,
educational level, experiences with medication use) and
sum scores in terms of the dependent variables (i.e.
knowledge of the concept of pharmacogenetics, attitude
towards pharmacogenetics).
Associations were expressed as odds ratios (OR) with
95% confidence intervals. ‘Knowledge’ and ‘attitude’ were
analyzed by combining the responses to three questions to
give a sum score. Respondents who answered ‘Yes’ to all
three questions assessing knowledge were considered to
have good knowledge of the concept of pharmacogenetics.
Respondents who answered ‘Yes’ to all three questions
assessing their attitude were considered to have a good at-
titude towards the implementation of pharmacogenetics.
The variable ‘interest to participate in pharmacogenetic
research’ was analyzed either as “Yes” or “No/I don’t
know”. Analyses were performed using PSAW Statistics,
Version 22 (IBM Corporation, Armonk, NY, USA).
Results
Respondents’ characteristics
We contacted thirteen community pharmacies that had
the highest number of eligible women, according to the
IADB.nl database. Eight of these pharmacies agreed to
participate in the study. Letters were successfully delivered
to 986 selected participants, and 219 (22.2%) returned a
completed questionnaire. The sampling method is
depicted in Fig. 1 and the general characteristics and med-
ical/medication history of the respondents are shown in
Table 1. The mean age of the respondents was 34 years,
which is older than that of all eligible women in the data-
base (N = 3689, mean = 29 years, p <0.001). The majority
of the respondents had an education level that was middle
(46.1%) or high (44.3%). 22 (10%) of the respondents were
pregnant at the time they filled in the questionnaire.
Fifty five (25.1%) of the respondents had one or more
chronic diseases, mostly asthma, allergy and skin condi-
tions. Of 163 who did not have a chronic disease, 47
(28.8%) had one or more family members with at least
one chronic disease. One participant did not answer this
question. Nearly half of all respondents had used some
medication during pregnancy, excluding folic acid and vita-
min supplements (n = 94, 42.9%). A history of experiencing
drug side-effects, not limited to the period of pregnancy,
was also common among the respondents (n = 93, 42.5%).
Furthermore, 70% of this subset of respondents admitted
to stopping their medication due to side-effects. Among all
respondents, 23.7% (n = 52) claimed that they had stopped
taking medication due to ineffectiveness.
Knowledge of pharmacogenetics
A large percentage of the respondents were aware of the
concept of pharmacogenetics (Fig. 2a). 142 (64.8%) an-
swered positively to all three questions that assessed
their background knowledge on pharmacogenetics.
However, only 50 (22.8%) of the respondents had heard
the term ‘pharmacogenetics’ before receiving this ques-
tionnaire, while 38 (17.4%) of them claimed that they
knew its meaning. Less than 10% of the respondents had
heard of a ‘DNA passport’, which is personalized identifi-
cation card containing genetic information to improve
drug prescribing (DNA passports are commercially avail-
able in the Netherlands). Three respondents described
the DNA passport correctly, while nine described it as
containing an individual’s genetic information in a
Fig. 1 Population sampling and data collection methods
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broader scope, without mentioning the relation to drug
use. Only one respondent had had a pharmacogenetic test,
while five others knew someone who had had such a test.
Respondents with a high or medium level of education
were more likely to agree with the statement “Do you
think that there could be differences between people in
their body's response to medication due to differences in
their DNA?”, than were respondents with a low level of
education ([OR for middle level of education = 4.84, 95%
CI 1.56, 15.0]; [OR for high level = 8.10, 95% CI 2.39,
27.51]) (Table 2). Respondents who had experience with
drug side-effects, either themselves or their family mem-
bers, were twice as likely to have a good knowledge of the
pharmacogenetics concept [OR = 2.06, 95% CI 1.16, 3.65].
Self-reported awareness of the term ‘pharmacogenetics’
and of the meaning of this term were not, however, associ-
ated with a good knowledge of pharmacogenetics.
Attitude towards pharmacogenetics
More than half of the respondents had a positive atti-
tude towards pharmacogenetics (Fig. 2b). 118 (53.9%)
answered positively to all three questions assessing their
attitude towards the implementation of pharmacogenet-
ics in any drug treatments that they may need in the fu-
ture. 20–30% of the respondents were unsure of whether
they would take a DNA test or would allow their doctors
to use their pharmacogenetic information in their drug
treatment. The most preferred method of DNA collec-
tion, voted as the first choice, was buccal swab collection
(57.8%), followed by saliva collection (25.4%), dried
blood spot (15%), and the least preferred method being
taking a blood sample (1.2%) (Additional file 2: Figure S1).
A positive attitude towards the implementation of
pharmacogenetics was associated with having good know-
ledge of pharmacogenetics [OR = 3.50, 95% CI 1.95, 6.30].
Other variables were not found to be significantly corre-
lated with a positive attitude towards pharmacogenetics
(Additional file 1: Table S1).
Interest to participate in pharmacogenetic research
We determined respondents’ interest to take part in fu-
ture pharmacogenetic research: 102 (46.6%) were posi-
tive, 31 (14.2%) answered ‘No’, while 85 (38.8%)
answered ‘Do not know’. Among those who responded
‘No’ or ‘Do not know’ (n = 116), the reason most often
given for not wanting to participate in such research was
that they were worried about the consequences (35.3%),
while some of them did not want their DNA or genetic
information to be used for research (12.9%). Many of
them also described their concerns in the open-ended
option provided and some of these are listed in Table 3.
In addition, nearly half of the respondents were inter-
ested in obtaining more information on pharmacogenet-
ics (n = 98, 44.7%), while the percentages of those who
Table 1 General characteristics and medical/medication history
of the respondents (N = 219)
Characteristics Respondents, n (%)a





Missing data 3 (1.4)
Living situation
Alone/divorced 10 (4.6)
Married/living with partner/parents/others 207 (94.5)
Missing data 2 (0.9)
History of chronic disease
Yes 55 (25.1)
Never 116 (53.0)
No, but a family member has 47 (21.5)
Missing data 1 (0.5)
History of medication use during pregnancyb
Yes 94 (42.9)
No 119 (54.3)
Do not know 5 (2.3)
Missing data 1 (0.5)
History of experiencing side-effects of medication
Yes 93 (42.5)
No 105 (47.9)
No, but a family member has 13 (5.9)
Do not know 6 (2.7)
Missing data 2 (0.9)
History of stopping medication use due to side-effects
Yes 71 (32.4)
No 142 (64.8)
No, but a family member has 4 (1.8)
Missing data 2 (0.9)
History of stopping medication use due to inefficacy
Yes 52 (23.7)
No 160 (73.1)
No, but a family member has 5 (2.3)
Missing data 2 (0.9)
Aware of the term ‘pharmacogenetics’
Yes 50 (22.8)
No 166 (75.8)
Missing data 3 (1.4)
Aware of the meaning of ‘pharmacogenetics’
Yes 38 (17.4)
No 178 (81.3)
Missing data 3 (1.4)
alow: primary school, lower general secondary education, and lower vocational
education; middle: higher general secondary education and intermediate vocational
education; high: higher vocational education and university; bexcluding folic acid
and other supplements
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declined or who were undecided were almost equal
(23.7% and 29.2%, respectively). The preferred source of
information was the internet (n = 103, 47.0%), followed
by an information leaflet (n = 91, 41.6%), advice from
their general practitioner (n = 90, 41.1%), and advice
from a pharmacist (n = 41, 18.7%).
Good knowledge of the concept of pharmacogenetics
and a positive attitude towards its implementation were
significantly associated with the interest to participate in
pharmacogenetic research [OR for ‘knowledge’ = 2.05,
95% CI 1.15, 3.66; OR for ‘attitude’ = 5.73, 95% CI 3.16,
10.37]. Women who had good knowledge and a positive
attitude were also more likely to be interested in obtaining
more information about the concept [OR for ‘knowledge’
= 1.85, 95% CI 1.03, 3.32; OR for ‘attitude’ = 2.25, 95% CI
1.29, 3.92].
Discussion
This study suggests that while most women who have
been pregnant are not familiar with the term ‘pharma-
cogenetics’, many do have some understanding of the
association between DNA and drug therapy effects.
Our results also show that while more than half of
formerly pregnant women are positive towards the use
of their genetic information in determining their future
drug therapy, many of them are either neutral or still
undecided.
Predictors of good knowledge and attitude towards
pharmacogenetics
We found educational level to be one of the predictors
of adequate knowledge on pharmacogenetics, while the
majority of the respondents had at least a medium level
of education. The high percentage of highly educated
women among our respondents (44.3%) is similar to the
percentage reported by Statistics Netherlands in 2016 for
women aged between 25 and 34 years (48%) [19]. The per-
centage of respondents who reported they had used medi-
cation during pregnancy (42.9%) is lower than the
percentage of the source population who had received any
prescription during pregnancy (71.4%, N = 3689), and also
lower than the percentage reported previously in the same
population (69.2%) [16]. We expect that the actual drug
use during pregnancy in our respondents was higher, since
our data is based on self-reported events and subject to re-
call bias.
Our finding that respondents who had experienced
drug side-effects themselves—or who had family mem-
bers with side-effects—were more likely to have a good
understanding and knowledge of the pharmacogenetics
Fig. 2 Knowledge and attitude towards pharmacogenetics among respondents (n= 219). a The responses to the questions assessing their background
knowledge of the concept of pharmacogenetics; b The responses to the questions assessing their attitude towards the implementation
of pharmacogenetics
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concept is consistent with the findings of Nielsen and
colleagues [7]. Others have also found a history of side-
effects to be a good motivation for pharmacogenetic
testing [10, 20], even if the individual is aware of the
possibility of the DNA sample being accessed without
the patient’s permission or if the sampling requires a
blood test [10].
Women in our study population were generally posi-
tive and optimistic regarding the use of pharmacogenet-
ics information for their future drug therapy. This
attitude towards pharmacogenetics was not influenced
by education level, chronic disease or a history of side-
effects, but was significantly associated with a good
understanding of the concept. The fact that when an-
swering questions about their attitudes many respon-
dents indicated they were undecided or unsure—rather
than giving a negative answer—is not surprising. After
all, a large majority of them might only have heard of
pharmacogenetics for the first time from the question-
naire in this study, which may well explain their conser-
vative opinions. Other reasons that might explain the
reluctance in accepting pharmacogenetics are the lack of
understanding or belief that this concept could help in
their drug treatment, or they might be worried about the
consequences [20, 21].
Our results suggest that neither a history of chronic
diseases nor medication use during pregnancy leads to a
more positive attitude or perception on pharmacogenet-
ics. In addition, the number of medications consumed
also did not determine the attitude towards pharmaco-
genetics among the public [7]. This finding shows that
the concept of pharmacogenetics can be universally ac-
cepted by the public, regardless of health status and dis-
ease burden; we predict the public may well accept the
use of pharmacogenetics as long as they are well in-
formed of its possibilities.
Interest in pharmacogenetic research
In our study, the respondents’ preferred sources of infor-
mation about pharmacogenetics were different to those
found in other studies. While we found the internet and
an information leaflet to be most favored, others report
the advice from doctors, a specialist or other healthcare
providers to be more popular [20, 22]. One of the pos-
sible explanations is that we provided a link to a reliable
website on pharmacogenetics in the questionnaire,
which might aid their decision to choose the internet.
Regardless of their choice, our questionnaire itself might
well stimulate participants’ interest in finding out more
about pharmacogenetics. Indeed, better knowledge on
the concept of pharmacogenetics, and a positive attitude
towards the implementation of pharmacogenetics were
associated with a high interest to participate in future
pharmacogenetic research. Concerns reported here such
as those regarding the privacy and anonymity of genetic
information —and possible misuse by employers or in-
surance companies—have also been reported by others
[8, 20, 23, 24]. This emphasizes the need for regulatory
measures to be established to protect patients’ privacy.
There are three main limitations to our study. First,
sampling bias may have arisen during the recruitment of
community pharmacies, since we could only select those
pharmacies registered in the pregnancy subset of
IADB.nl, and several pharmacists declined to participate
because the topic was deemed too difficult for their
population. Second, information bias may also have
affected our results in terms of respondents’ know-
ledge about pharmacogenetics. Both the cover letter
and the questionnaire provided respondents with a
brief explanation of pharmacogenetics. While this in-
formation was intended to introduce this concept to
those who were not familiar with it, and to promote
interest in filling in the questionnaire [22, 23], it may
have assisted respondents in answering the questions,
and resulted in a higher level of knowledge being re-
ported. Third, there was a selection bias towards
women who were more health-literate, and away from
those who chose not to respond to the questionnaire.
Although our survey results may not represent the
entire Dutch female population, they do focus on a
population who might be pregnant, and provide a
useful picture of their views on pharmacogenetics and
its implementation in their drug therapy.
Table 3 Reasons not to participate in pharmacogenetic research
(N = 116)
Reasons Number Percenta
‘I am worried about the consequences’ 41 35.3
‘I do not want my DNA/genetic
information to be used in research’
15 12.9
‘I am not interested in pharmacogenetic
research’
10 8.6
‘I do not understand the benefit of
genetic testing’
8 6.9
Others (answers in open-ended option):
‘Need more information about the
research before I can decide’
2 19.0
‘Concerned about the privacy/anonymity
of my genetic information and afraid it
will be used/abused by insurance company,
employer, etc.’
14 12.1
‘Need more time to think about this’ 5 4.3
‘Lack of understanding or doubtful about this
concept’
3 2.6
‘Do not like/no time to participate in research’ 2 1.7
Other/personal reasons 5 4.3
apercentages may add up to more than 100 because respondents could give
more than one answer
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A key strength of our study is that we are the first to re-
port on the knowledge and attitude regarding pharmaco-
genetics specifically in a formerly pregnant population.
While awareness of pharmacogenetics itself appears to be
low, women’s knowledge and attitude on the concept is
good. Their acceptance and concerns regarding pharmaco-
genetic issues do not appear to be very different from
those among the public and patient population as reported
elsewhere [7, 8, 10, 20, 22]. Future research in this area
could include longitudinal studies of pregnant women and
also exploring attitudes to DNA testing for pharmacoge-
netic information, before, during and after pregnancy.
Conclusion
The substantial level of interest in pharmacogenetics
among formerly pregnant women is encouraging; there-
fore it is worthwhile pursuing its application in personal-
ized drug therapy for safer use of drugs during pregnancy.
Several designs in genetic epidemiology research may pave
ways to understand the role of pharmacogenetics in fetal
drug exposure and outcome. A question remained un-
answered is whether the privacy and confidentiality of the
genetic information can be adequately assured, in both re-
search and clinical settings, which need to be addressed by
researchers and health authorities.
Additional files
Additional file 1: Questionnaire used in the survey (translated in English).
Table S1: The likelihood of having a good attitude towards
pharmacogenetics testing given respondent characteristics (PDF 510 kb)
Additional file 2: Figure S1. Preferred DNA collection methods among
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